A model predictive control based scheduling method for HIV therapy

Journal of Theoretical Biology

Volumn 238, Issue 2, 2006, Pages 368-382

  Zurakowski, Ryan ^a   Teel, Andrew R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

Antiretroviral therapy; Nonlinear control; Viral dynamics

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MATHEMATICAL MODEL; MEDICAL INFORMATION; MOTIVATION; PRIORITY JOURNAL; SIMULATION; TREATMENT OUTCOME; TREATMENT PLANNING;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 29244476878     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2005.05.004     Document Type: Article

References (87)

1. U.L. Abbas, and J.W. Mellors Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward Proc. Natl Acad. Sci. USA 99 21 2002 13377 13378
2. H. Altes, D. Wodarz, and V. Jansen The dual role of CD4 T helper cells in the infection dynamics of HIV and their importance for vaccination J. Theor. Biol. 214 4 2002 633 646
3. M. Altfeld, E. Rosenberg, R. Shankarappa, J. Mukherjee, F. Hecht, R. Eldridge, M. Addo, S. Poon, M. Phillips, G. Robbins, P. Sax, S. Boswell, J. Kahn, C. Brander, P. Goulder, J. Levy, J. Mullins, and B. Walker Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection J. Exp. Med. 193 2 2001 169 180
4. M. Altfeld, T. Allen, X. Yu, M. Johnston, D. Agrawal, B. Korber, D. Montefiori, D. O'Connor, B. Davis, P. Lee, E. Maier, J. Harlow, P. Goulder, C. Brander, E. Rosenberg, and B. Walker HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus Nature 420 6914 2002 434 439
5. M. Altfeld, J.V. Lunzen, N. Frahm, X. Yu, C. Schneider, R. Eldridge, M. Feeney, D. Meyer-Olson, H. Stellbrink, and B. Walker Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV1 infection J. Clin. Invest. 109 6 2002 837 843
6. J. Ananworanich, R. Nuesch, M.L. Braz, P. Chetchotisakd, A. Vibhagool, S. Wicharuk, K. Ruxrungtham, H. Furrer, D. Cooper, B. Hirschel, E. Bernasconi, M. Cavassini, C. Ebnöther, C. Fagard, D. Genné, N. Khanna, L. Perrin, P. Phanupak, S. Ubolyam, P. Vernazza, S. Yerly, and S.H.C. Study Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial AIDS 17 15 2003 F33 F37
7. V. Appay, L. Papagno, C. Spina, P. Hansasuta, A. King, L. Jones, G. Ogg, S. Little, A. McMichael, D. Richman, and S. Rowland-Jones Dynamics of T cell responses in HIV infection J. Immunol. 168 7 2002 3660 3666
8. R. Arnaout, M. Nowak, and D. Wodarz HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc. R. Soc. Lond. B Biol. Sci. 267 1450 2000 1347 1354
9. B. Autran, and G. Carcelain AIDS. Boosting immunity to HIV - can the virus help? Science 290 5493 2000 946 949
10. M. Betts, D. Ambrozak, D. Douek, S. Bonhoeffer, J. Brenchley, J. Casazza, R. Koup, and L. Picker Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection J. Virol. 75 24 2001 11983 11991
11. J.N. Blankson, J.E. Gallant, T.C. Quinn, J.G. Bartlett, and R.F. Siliciano Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients JAMA 288 2 2002 162 164
12. S. Bonhoeffer, M. Rembiszewski, G. Ortiz, and D. Nixon Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection AIDS 14 15 2000 2313 2322
13. M. Brandt, and G. Chen Feedback control of a biodynamical model of HIV-1 IEEE Trans. Biomed. Eng. 48 7 2001 754 759
14. R. Bucy, and J. Kilby Perspectives on inducing efficient immune control of HIV-1 replication - a new goal for HIV therapeutics? AIDS 15 Suppl 2 2001 S36 S42
15. G. Carcelain, R. Tubiana, A. Samri, V. Calvez, C. Delaugerre, H. Agut, C. Katlama, and B. Autran Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection J. Virol. 75 1 2001 234 241
16. R. Davey, N. Bhat, C. Yoder, T. Chun, J. Metcalf, R. Dewar, V. Natarajan, R. Lempicki, J. Adelsberger, K. Miller, J. Kovacs, M. Polis, R. Walker, J. Falloon, H. Masur, D. Gee, M. Baseler, D. Dimitrov, A. Fauci, and H. Lane HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression Proc. Natl Acad. Sci. USA 96 26 1999 15109 15114
17. F. de Souza Modeling the dynamics of HIV-1 and CD4 and CD8 lymphocytes IEEE Eng. Med. Biol. Mag. 18 1 1999 21 24
18. G. D'Offizi, C. Montesano, C. Agrati, C. Gioia, M. Amicosante, S. Topino, P. Narciso, L. Pucillo, G. Ippolito, and F. Poccia Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption AIDS 16 18 2002 2431 2438
19. K. Dorman, A. Kaplan, K. Lange, and J. Sinsheimer Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1? J. Acquir. Immune Defic. Syndr. 25 5 2000 398 402
20. D. Douek, J. Brenchley, M. Betts, D. Ambrozak, B. Hill, Y. Okamoto, J. Casazza, J. Kuruppu, K. Kunstman, S. Wolinsky, Z. Grossman, M. Dybul, A. Oxenius, D. Price, M. Connors, and R. Koup HIV preferentially infects HIV-specific CD4+ T cells Nature 417 6884 2002 95 98
21. M. Dybul, T. Chun, C. Yoder, B. Hidalgo, M. Belson, K. Hertogs, B. Larder, R. Dewar, C. Fox, C. Hallahan, J. Justement, S. Migueles, J. Metcalf, R. Davey, M. Daucher, P. Pandya, M. Baseler, D. Ward, and A. Fauci Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters Proc. Natl Acad. Sci. USA 98 26 2001 15161 15166
22. C. Fagard, A. Oxenius, H. Günthard, F. Garcia, M.L. Braz, G. Mestre, M. Battegay, H. Furrer, P. Vernazza, E. Bernasconi, A. Telenti, R. Weber, D. Leduc, S. Yerly, D. Price, S.J. Dawson, T. Klimkait, T.V. Perneger, A. McLean, B. Clotet, J.M. Gatell, L. Perrin, M. Plana, R. Phillips, B. Hirschel, and S.H.C. Study A prospective trial of structured treatment interruptions in human immunodeficiency virus infection Arch. Intern. Med. 163 10 2003 1220 1226
23. D. Finzi, J. Blankson, J. Siliciano, J. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewicz, F. Lori, C. Flexner, T. Quinn, R. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R. Siliciano Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Nat. Med. 5 5 1999 512 517
24. M. Fischer, R. Hafner, C. Schneider, A. Trkola, B. Joos, H. Joller, B. Hirschel, R. Weber, H.F. Günthard, and S.H.C. Study HIV RNA in plasma rebounds within days during structured treatment interruptions AIDS 17 2 2003 195 199
25. S. Frost Dynamics and evolution of HIV-1 during structured treatment interruptions AIDS Rev. 4 3 2002 119 127
26. S. Frost, J. Martinez-Picado, L. Ruiz, B. Clotet, and A. Brown Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection J. Virol. 76 3 2002 968 979
27. F. Garcia, M. Plana, G. Ortiz, S. Bonhoeffer, A. Soriano, C. Vidal, A. Cruceta, M. Arnedo, C. Gil, G. Pantaleo, T. Pumarola, T. Gallart, D. Nixon, J. Miró, and J. Gatell The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection AIDS 15 9 2001 F29 F40
28. T. Gegeny Surviving with HIV in the HAART era: emerging challenges Res. Initiat. Treat. Action 6 3 2000 12 14
29. S. Gloster, P. Newton, D. Cornforth, J. Lifson, I. Williams, G. Shaw, and P. Borrow Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection AIDS 18 5 2004 749 755
30. C. Gray, J. Lawrence, E. Ranheim, M. Vierra, M. Zupancic, M. Winters, J. Altman, J. Montoya, A. Zolopa, J. Schapiro, A. Haase, and T. Merigan Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells AIDS Res. Hum. Retroviruses 16 14 2000 1357 1369
31. Grimm, G., Messina, M., Teel, A., Tuna, S., 2003. Model predictive control when a local control lyapunov function is not available. In: Proceedings of the 2003 American Control Conference, vol. 5. pp. 4125-4130.
32. R.M. Gulick Structured treatment interruption in patients infected with HIV: a new approach to therapy Drugs 62 2 2002 245 253
33. T. Harrer, E. Harrer, S. Kalams, P. Barbosa, A. Trocha, R. Johnson, T. Elbeik, M. Feinberg, S. Buchbinder, and B. Walker Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load J. Immunol. 156 7 1996 2616 2623
34. T. Harrer, E. Harrer, S. Kalams, T. Elbeik, S. Staprans, M. Feinberg, Y. Cao, D. Ho, T. Yilma, A. Caliendo, R. Johnson, S. Buchbinder, and B. Walker Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection AIDS Res. Hum. Retroviruses 12 7 1996 585 592
35. P. Haslett, D. Nixon, Z. Shen, M. Larsson, W. Cox, R. Manandhar, S. Donahoe, and G. Kaplan Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy J. Infect. Dis. 181 4 2000 1264 1272
36. H. Hatano, S. Vogel, C. Yoder, J. Metcalf, R. Dewar, R. Davey, and M. Polis Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression AIDS 14 10 2000 1357 1363
37. D.V. Havlir Structured intermittent treatment for HIV disease: necessary concession or premature compromise? Proc. Natl Acad. Sci. USA 99 1 2002 4 6
38. D. Ho, A. Neumann, A. Perelson, W. Chen, J. Leonard, and M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 6510 1995 123 126
39. Hoffmann, C., Kamps, B. (Eds.), 2003. HIV Medicine. Flying Publisher.
40. X. Jin, D. Bauer, S. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. Irwin, J. Safrit, J. Mittler, L. Weinberger, L. Kostrikis, L. Zhang, A. Perelson, and D. Ho Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques J. Exp. Med. 189 6 1999 991 998
41. S. Kalams, S. Buchbinder, E. Rosenberg, J. Billingsley, D. Colbert, N. Jones, A. Shea, A. Trocha, and B. Walker Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection J. Virol. 73 8 1999 6715 6720
42. S. Kalams, P. Goulder, A. Shea, N. Jones, A. Trocha, G. Ogg, and B. Walker Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy J. Virol. 73 8 1999 6721 6728
43. D. Kaufmann, and E. Rosenberg The value of preserving HIV-specific immune responses J. HIV Ther. 8 1 2003 19 25
44. Kaufmann, D., Lichterfeld, M., Altfeld, M., Allen, T., Johnston, M., Lee, P., Wagner, B., Kalife, E., Strick, D., Rosenberg, E., Walker, B.D., 2004. Limited durability of immune control following treated acute hiv infection. In: The 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA.
45. Kellett, C., Teel, A., 2002. On robustness of stability and lyapunov functions for discontinuous difference equations. In: Proceedings of the 41st IEEE Conference on Decision and Control. pp. 4282-4287.
46. D. Kirschner, and G. Webb A mathematical model of combined drug therapy of HIV infection J. Theor. Med. 1 1997 25 34
47. R. Koup, J. Safrit, Y. Cao, C. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. Ho Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J. Virol. 68 7 1994 4650 4655
48. J. Lisziewicz, E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, and F. Lori Control of HIV despite the discontinuation of antiretroviral therapy N. Engl. J. Med. 340 21 1999 1683 1684
49. F. Lori, and J. Lisziewicz Structured treatment interruptions for the management of HIV infection JAMA 286 23 2001 2981 2987
50. F. Lori, R. Maserati, A. Foli, E. Seminari, J. Timpone, and J. Lisziewicz Structured treatment interruptions to control HIV-1 infection Lancet 355 9200 2000 287 288
51. C. Manegold, C. Hannoun, A. Wywiol, M. Dietrich, S. Polywka, C. Chiwakata, and S. Günther Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy Clin. Infect. Dis. 32 1 2001 144 148
52. J. Martinez-Picado, K. Morales-Lopetegi, T. Wrin, J.G. Prado, S.D.W. Frost, C.J. Petropoulos, B. Clotet, and L. Ruiz Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions AIDS 16 6 2002 895 899
53. D. Mayne, J. Rawlings, C. Rao, and P. Scokaert Constrained model predictive control: stability and optimality Automatica 36 2000 789 814
54. A. McMichael, and S. Rowland-Jones Cellular immune responses to HIV Nature 410 6831 2001 980 987
55. Messina, M., Tuna, S., Teel, A., 2004. Robust stabilization of discrete-time nonlinear systems by certainty equivalence output feedback with applications to model predictive control. In: Proceedings of the 2004 American Control Conference, vol. 3. pp. 2202-2207.
56. S. Migueles, A. Laborico, W. Shupert, M. Sabbaghian, R. Rabin, C. Hallahan, D.V. Baarle, S. Kostense, F. Miedema, M. McLaughlin, L. Ehler, J. Metcalf, S. Liu, and M. Connors HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors Nat. Immunol. 3 11 2002 1061 1068
57. A. Mocroft, L. Ruiz, P. Reiss, B. Ledergerber, C. Katlama, A. Lazzarin, F. Goebel, A. Phillips, B. Clotet, and J. Lundgren Virological rebound after suppression on highly active antiretroviral therapy AIDS 17 12 2003 1741 1751
58. L. Mollet, T. Li, A. Samri, C. Tournay, R. Tubiana, V. Calvez, P. Debré, C. Katlama, and B. Autran Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups J. Immunol. 165 3 2000 1692 1704
59. L. Montaner Structured treatment interruptions to control HIV-1 and limit drug exposure Trends Immunol. 22 2 2001 92 96
60. R. Moss, F. Jensen, and D. Carlo Insights into HIV-specific immune function: implications for therapy and prevention in the new millennium Clin. Immunol. 95 2 2000 79 84
61. A. Neumann, R. Tubiana, V. Calvez, C. Robert, T. Li, H. Agut, B. Autran, and C. Katlama HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group AIDS 13 6 1999 677 683
62. G. Ortiz, D. Nixon, A. Trkola, J. Binley, X. Jin, S. Bonhoeffer, P. Kuebler, S. Donahoe, M. Demoitie, W. Kakimoto, T. Ketas, B. Clas, J. Heymann, L. Zhang, Y. Cao, A. Hurley, J. Moore, D. Ho, and M. Markowitz HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy J. Clin. Invest. 104 6 1999 R13 R18
63. G. Ortiz, M. Wellons, J. Brancato, H. Vo, R. Zinn, D. Clarkson, K.V. Loon, S. Bonhoeffer, G. Miralles, D. Montefiori, J. Bartlett, and D. Nixon Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects Proc. Natl Acad. Sci. USA 98 23 2001 13288 13293
64. M. Ostrowski, J. Gu, C. Kovacs, J. Freedman, M. Luscher, and K. MacDonald Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses J. Infect. Dis. 184 10 2001 1268 1278
65. A. Oxenius, D. Price, H. Günthard, S. Dawson, C. Fagard, L. Perrin, M. Fischer, R. Weber, M. Plana, F. García, B. Hirschel, A. McLean, and R. Phillips Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection Proc. Natl Acad. Sci. USA 99 21 2002 13747 13752
66. B. Palmer, E. Boritz, N. Blyveis, and C. Wilson Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication J. Virol. 76 12 2002 5925 5936
67. E. Papasavvas, G. Ortiz, R. Gross, J. Sun, E. Moore, J. Heymann, M. Moonis, J. Sandberg, L. Drohan, B. Gallagher, J. Shull, D. Nixon, J. Kostman, and L. Montaner Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption J. Infect. Dis. 182 3 2000 766 775
68. E. Papasavvas, R.M. Grant, J. Sun, A. Mackiewicz, M. Pistilli, C. Gallo, J.R. Kostman, K. Mounzer, J. Shull, and L.J. Montaner Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients AIDS 17 16 2003 2337 2343
69. A. Perelson, and P. Nelson Mathematical analysis of hiv-1 dynamics in vivo SIAM Rev. 41 1 1999 3 44
70. A. Perelson, A. Neumann, M. Markowitz, J. Leonard, and D. Ho HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time Science 271 5255 1996 1582 1586
71. A. Phillips, S. Staszewski, F. Lampe, M. Youle, S. Klauke, M. Bickel, C. Sabin, H. Doerr, M. Johnson, C. Loveday, and V. Miller Human immunodeficiency virus rebound after suppression to < 400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression J. Infect. Dis. 186 8 2002 1086 1091
72. C. Pitcher, C. Quittner, D. Peterson, M. Connors, R. Koup, V. Maino, and L. Picker HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression Nat. Med. 5 5 1999 518 525
73. B. Rodes, C. Toro, E. Paxinos, E. Poveda, M. Martinez-Padial, J. Benito, V. Jimenez, T. Wrin, S. Bassani, and V. Soriano Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection AIDS 18 8 2004 1109 1116
74. E. Rosenberg, and B. Walker HIV type 1-specific helper T cells: a critical host defense AIDS Res. Hum. Retroviruses 14 Suppl 2 1998 S143 S147
75. E. Rosenberg, J. Billingsley, A. Caliendo, S. Boswell, P. Sax, S. Kalams, and B. Walker Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia Science 278 5342 1997 1447 1450
76. E. Rosenberg, L. LaRosa, T. Flynn, G. Robbins, and B. Walker Characterization of HIV-1-specific T-helper cells in acute and chronic infection Immunol. Lett. 66 1-3 1999 89 93
77. E. Rosenberg, M. Altfeld, S. Poon, M. Phillips, B. Wilkes, R. Eldridge, G. Robbins, R. D'Aquila, P. Goulder, and B. Walker Immune control of HIV-1 after early treatment of acute infection Nature 407 6803 2000 523 526
78. L. Ruiz, J. Martinez-Picado, J. Romeu, R. Paredes, M. Zayat, S. Marfil, E. Negredo, G. Sirera, C. Tural, and B. Clotet Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression AIDS 14 4 2000 397 403
79. L. Ruiz, G. Carcelain, J. Martínez-Picado, S. Frost, S. Marfil, R. Paredes, J. Romeu, E. Ferrer, K. Morales-Lopetegi, B. Autran, and B. Clotet HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection AIDS 15 9 2001 F19 F27
80. J. Schmitz, M. Kuroda, S. Santra, V. Sasseville, M. Simon, M. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. Scallon, J. Ghrayeb, M. Forman, D. Montefiori, E. Rieber, N. Letvin, and K. Reimann Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes Science 283 5403 1999 857 860
81. B. Schweighardt, G.M. Ortiz, R.M. Grant, M. Wellons, G.D. Miralles, L.G. Kostrikis, J.A. Bartlett, and D.F. Nixon Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions AIDS 16 17 2002 2342 2344
82. C.L. Tremblay, J.L. Hicks, L. Sutton, F. Giguel, T. Flynn, M. Johnston, P.E. Sax, B.D. Walker, M.S. Hirsch, E.S. Rosenberg, and R.T. D'Aquila Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection AIDS 17 7 2003 1086 1089
83. L. Wein, S. Zenios, and M. Nowak Dynamic multidrug therapies for HIV: a control theoretic approach J. Theor. Biol. 185 1 1997 15 29
84. D. Wodarz Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance J. Theor. Biol. 213 3 2001 447 459
85. D. Wodarz, and M. Nowak Specific therapy regimes could lead to long-term immunological control of HIV Proc. Natl Acad. Sci. USA 96 25 1999 14464 14469
86. D. Wodarz, R. Arnaout, M. Nowak, and J. Lifson Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus Philos. Trans. R. Soc. Lond. B Biol. Sci. 355 1400 2000 1021 1029
87. O. Yang, P. Sarkis, A. Ali, J. Harlow, C. Brander, S. Kalams, and B. Walker Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes J. Exp. Med. 197 10 2003 1365 1375